| Jolanta Siegien, MD | |
|
111 Highway 70 E, Dickson, TN 37055-2080 | |
| (615) 740-3426 | |
| (615) 441-9615 |
| Full Name | Jolanta Siegien |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 34 Years |
| Location | 111 Highway 70 E, Dickson, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124066683 | NPI | - | NPPES |
| 3887136 | Medicaid | TN | |
| 4206806 | Other | TN | BLUE CROSS BLUE SHIELD |
| 7974350 | Other | TN | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 0000034133 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Thomas West Hospital | Nashville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Warner Physician Services Pc | 0345602801 | 46 |
News Archive
Anti-inflammatory substances based on components of human cells could one day improve treatment in patients. Researchers at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed a method for producing those substances with controlled quality.
Northeastern University professor Mark C. Williams and colleague Ioana Vladescu have discovered a novel method for studying the DNA binding of small molecules with unprecedented accuracy.
Product innovation and reformulation, along with appropriate nutrition labeling, are key measures that the food industry can take to challenge obesity concluded academic and food industry experts meeting recently in Munich.
Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.
› Verified 2 days ago
| Entity Name | Saint Thomas Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437194669 PECOS PAC ID: 1557269354 Enrollment ID: O20031230000470 |
News Archive
Anti-inflammatory substances based on components of human cells could one day improve treatment in patients. Researchers at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed a method for producing those substances with controlled quality.
Northeastern University professor Mark C. Williams and colleague Ioana Vladescu have discovered a novel method for studying the DNA binding of small molecules with unprecedented accuracy.
Product innovation and reformulation, along with appropriate nutrition labeling, are key measures that the food industry can take to challenge obesity concluded academic and food industry experts meeting recently in Munich.
Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.
› Verified 2 days ago
| Entity Name | Warner Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770272221 PECOS PAC ID: 0345602801 Enrollment ID: O20230815002672 |
News Archive
Anti-inflammatory substances based on components of human cells could one day improve treatment in patients. Researchers at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed a method for producing those substances with controlled quality.
Northeastern University professor Mark C. Williams and colleague Ioana Vladescu have discovered a novel method for studying the DNA binding of small molecules with unprecedented accuracy.
Product innovation and reformulation, along with appropriate nutrition labeling, are key measures that the food industry can take to challenge obesity concluded academic and food industry experts meeting recently in Munich.
Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jolanta Siegien, MD 111 Highway 70 E, Dickson, TN 37055-2080 Ph: (615) 740-3426 | Jolanta Siegien, MD 111 Highway 70 E, Dickson, TN 37055-2080 Ph: (615) 740-3426 |
News Archive
Anti-inflammatory substances based on components of human cells could one day improve treatment in patients. Researchers at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed a method for producing those substances with controlled quality.
Northeastern University professor Mark C. Williams and colleague Ioana Vladescu have discovered a novel method for studying the DNA binding of small molecules with unprecedented accuracy.
Product innovation and reformulation, along with appropriate nutrition labeling, are key measures that the food industry can take to challenge obesity concluded academic and food industry experts meeting recently in Munich.
Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.
› Verified 2 days ago
Stephanie Alison Hatcher, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 111 Highway 70 E, Dickson, TN 37055 Phone: 615-326-2443 Fax: 615-326-2440 | |
Mydhili Challa, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 111 Hwy 70 E, Dickson, TN 37055 Phone: 615-446-0446 |